Publications by authors named "Stephen P Hack"

Claim this Profile
M
Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy.
Yulei Wang, Yinghui Guan, Alexander R Abbas, Yuji Sano, Saket Jain, Stephen P Hack

Cell Rep Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial.
Teresa Macarulla, Zhenggang Ren, Hong Jae Chon, Joon Oh Park, Jin Won Kim, Stephen P Hack

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.
Richard S Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, Daneng Li, Adam M Burgoyne, Stephen P Hack

Lancet Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial - Authors' reply.
Pierce K H Chow, Stephen P Hack, Jessica H Spahn, Adam C Yopp

Lancet· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Shukui Qin, Minshan Chen, Ann-Lii Cheng, Ahmed O Kaseb, Masatoshi Kudo, Stephen P Hack

Lancet· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework.
Colby S Shemesh, Phyllis Chan, Mathilde Marchand, Antonio Gonçalves, Shweta Vadhavkar, Stephen P Hack

Clin Pharmacol Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab: an investigational agent for the treatment of biliary tract cancer.
Stephen P Hack, Andrew X Zhu

Expert Opin Investig Drugs· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.
Stephen P Hack, Wendy Verret, Sohail Mulla, Bo Liu, Yulei Wang

Ther Adv Med Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Stephen P Hack, Andrew X Zhu, Yulei Wang

Front Immunol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Michael S Lee, Baek-Yeol Ryoo, Chih-Hung Hsu, Kazushi Numata, Stacey Stein, Stephen P Hack

Lancet Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.
Stephen P Hack, Jessica Spahn, Minshan Chen, Ann-Lii Cheng, Ahmed Kaseb

Future Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.
Manish A Shah, Yung-Jue Bang, Florian Lordick, Maria Alsina, Meng Chen, Stephen P Hack

JAMA Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.
Johanna C Bendell, Howard Hochster, Lowell L Hart, Irfan Firdaus, Joseph R Mace, Stephen P Hack

Oncologist· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Kelong Han, Jin Y Jin, Mathilde Marchand, Stephen Eppler, Nicholas Choong, Stephen P Hack

Cancer Chemother Pharmacol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
James Larkin, Paolo A Ascierto, Brigitte Dréno, Victoria Atkinson, Gabriella Liszkay, Stephen P Hack

N Engl J Med· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.
Stephen P Hack, Jean-Marie Bruey, Hartmut Koeppen

Oncotarget· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Giao Tran, Stephen P Hack, Annette Kerr, Leanne Stokes, Peter Gibbs

Asia Pac J Clin Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer.
Johanna C Bendell, Thomas J Ervin, David Gallinson, Jaswinder Singh, James A Wallace, Stephen P Hack

Clin Colorectal Cancer· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of delta-opioid receptor function in the midbrain after chronic morphine treatment.
Stephen P Hack, Elena E Bagley, Billy C H Chieng, MacDonald J Christie

J Neurosci· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GABA transporter currents activated by protein kinase A excite midbrain neurons during opioid withdrawal.
Elena E Bagley, Michelle B Gerke, Christopher W Vaughan, Stephen P Hack, MacDonald J Christie

Neuron· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serotonergic and nonserotonergic dorsal raphe neurons are pharmacologically and electrophysiologically heterogeneous.
Silvia Marinelli, Stephen A Schnell, Stephen P Hack, MacDonald J Christie, Martin W Wessendorf

J Neurophysiol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptations in adenosine signaling in drug dependence: therapeutic implications.
Stephen P Hack, Macdonald J Christie

Crit Rev Neurobiol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro.
Stephen P Hack, Christopher W Vaughan, MacDonald J Christie

Neuropharmacology· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular actions of opioids on periaqueductal grey neurons from C57B16/J mice and mutant mice lacking MOR-1.
Christopher W Vaughan, Elena E Bagley, Geoffrey M Drew, Alwin Schuller, John E Pintar, Stephen P Hack

Br J Pharmacol· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis